116 related articles for article (PubMed ID: 12884814)
21. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
22. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
[TBL] [Abstract][Full Text] [Related]
23. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment.
Maisnar V; Radocha J; Büchler T; Bláha V; Malý J; Hájek R
Eur J Haematol; 2007 Oct; 79(4):305-9. PubMed ID: 17803678
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.
Corso A; Zappasodi P; Barbarano L; Petrucci MT; Palumbo A; Caravita T; Mangiacavalli S; Cafro AM; Varettoni M; Gay F; Morra E; Lazzarino M
Leuk Res; 2009 Sep; 33(9):e145-9. PubMed ID: 19375164
[TBL] [Abstract][Full Text] [Related]
25. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
26. [Thalidomide therapy in patients with refractory or relapsed multiple myeloma].
Ochiai N; Shimazaki C; Uchida R; Fuchida S; Okano A; Ashihara E; Inaba T; Fujita N; Adachi Y; Nishio A; Nakagawa M
Rinsho Ketsueki; 2002 Dec; 43(12):1045-9. PubMed ID: 12607993
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
28. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
[TBL] [Abstract][Full Text] [Related]
29. Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma.
Huang SY; Tang JL; Yao M; Ko BS; Hong RL; Tsai W; Wang CH; Tien HF; Shen MC; Chen YC
Ann Hematol; 2003 Sep; 82(9):558-64. PubMed ID: 12898185
[TBL] [Abstract][Full Text] [Related]
30. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
31. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
[TBL] [Abstract][Full Text] [Related]
32. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K;
Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523
[TBL] [Abstract][Full Text] [Related]
33. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
Wang M; Weber DM; Delasalle K; Alexanian R
Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221
[TBL] [Abstract][Full Text] [Related]
34. Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.
Bemardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):129-33. PubMed ID: 16767919
[TBL] [Abstract][Full Text] [Related]
35. [Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma].
Kyrcz-Krzemień S; Helbig G; Stella-Hołowiecka B; Hołowiecki J
Wiad Lek; 2003; 56(5-6):227-32. PubMed ID: 14526479
[TBL] [Abstract][Full Text] [Related]
36. Thalidomide in refractory and relapsing multiple myeloma.
Bladé J; Esteve J; Rosiñol L; Perales M; Montoto S; Tuset M; Montserrat E
Semin Oncol; 2001 Dec; 28(6):588-92. PubMed ID: 11740814
[TBL] [Abstract][Full Text] [Related]
37. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
[TBL] [Abstract][Full Text] [Related]
38. Thromboembolism in patients on thalidomide for myeloma.
Bowcock SJ; Rassam SM; Ward SM; Turner JT; Laffan M
Hematology; 2002 Feb; 7(1):51-3. PubMed ID: 12171777
[TBL] [Abstract][Full Text] [Related]
39. Thalidomide as initial therapy for early-stage myeloma.
Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE
Leukemia; 2003 Apr; 17(4):775-9. PubMed ID: 12682636
[TBL] [Abstract][Full Text] [Related]
40. [Desirable and undesirable effects of thalidomide in patients with multiple myeloma].
Foldyna D; Kamelander J; Krejcí M; Hájek R
Vnitr Lek; 2003 Nov; 49(11):859-68. PubMed ID: 14689682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
